LatchBio’s Post

Culture Biosciences’ cloud-connected, high-throughput bioreactor platform can reproducibly process and optimize CHO cell culture experiments with scalable results. Data presented in this white paper by engineers in Culture’s Cloud Lab demonstrate upstream bioprocesses to develop, optimize and scale cell culture processes. With access to significant bioreactor capacity leveraging advanced analytical software to generate insights faster, clients working with Culture can spend their time focusing on what matters most: developing critical therapeutics for the patients who need them. #processdevelopment #processoptimization #mAb #CHO https://lnkd.in/eqghbyz4

“One of the biggest gaps in drug discovery today is achieving a deep understanding of function … Scientists need not just single-cell analysis, but single-cell functional analysis.”    How can technology like #Lightcast, which enables single-platform multifunctional assay workflows, help usher in a new era of scalable, flexible single-cell analysis? Kathrin Herbst, our Director of Science & Business Development, sheds some light on the matter in this article for Technology Networks : https://lnkd.in/eqNsFixw   #drugdiscovery #microfluidics #antibodydiscovery #singlecellanalysis #biotechnology

"Fail fast" is a guiding principle for innovation — if you can quickly weed out what doesn't work, you'll be better positioned to find out what does. But in the world of drug development, the current limitations of laboratory technologies mean that failures are slow and drawn out, often over years or even decades...which of course means that meaningful discoveries are even slower to emerge. In this great piece, Kathrin Herbst sheds some light on the importance of moving beyond the reach of today's single-cell platforms to achieve truly scalable, *functional* single-cell analysis. Platforms like Lightcast have the potential to help researchers "fail" faster to succeed faster in all sorts of laboratory applications: antibody discovery, cell line development, #CRISPR editing... Give it a read to learn more!

Culture Biosciences’ cloud-connected, high-throughput bioreactor platform can reproducibly process and optimize CHO cell culture experiments with scalable results. Data presented in this white paper by engineers in Culture’s Cloud Lab demonstrate upstream bioprocesses to develop, optimize and scale cell culture processes. With access to significant bioreactor capacity leveraging advanced analytical software to generate insights faster, clients working with Culture can spend their time focusing on what matters most: developing critical therapeutics for the patients who need them. #processdevelopment #processoptimization #mAb #CHO https://lnkd.in/eqghbyz4

Culture Biosciences’ cloud-connected, high-throughput bioreactor platform can reproducibly process and optimize CHO cell culture experiments with scalable results. Data presented in this white paper by engineers in Culture’s Cloud LabTM demonstrate upstream bioprocesses to develop, optimize and scale cell culture processes. With access to significant bioreactor capacity leveraging advanced analytical software to generate insights faster, Clients working with Culture can spend their time focusing on what matters most; developing critical therapeutics for the patients who need them. #processdevelopment #processoptimization #mAb #CHO https://lnkd.in/eqghbyz4

Interested in cloud-connected upstream process development and optimization. Learn more by downloading Culture Biosciences’ white paper. #cloudconnectivity #processdevelopment #bioreactor #bioprocess

𝐂𝐞𝐥𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $𝟑𝟑.𝟗 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟐𝟖  𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: bit.ly/4f2YbNu Cell Analysis Market is projected to reach USD 33.9 billion by 2028 from USD 20.2 billion in 2023, at a CAGR of 10.9% during the forecast period. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Danaher Corporation, Thermo Fisher Scientific, Becton, Dickinson and Company, GE HealthCare, Merck, Agilent Technologies 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐭𝐡𝐚𝐭 𝐚𝐫𝐞 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲 Nexcelom      Deepcell      Axion BioSystems      Spatial Genomics, Inc. ACEA Biosciences      Ionpath      RareCyte, Inc.  seqWell Pattern Bioscience      CYTENA      FlowJo      LumaCyte      Sphere Fluidics Limited Biotron Healthcare (India) Pvt. Ltd Meridian Life Science-Academic (previously Bioline) Relation      Celldom, Inc.  AdvanDx      Samplix      Levenberg Lab SEED Biosciences      One Biosciences      Phase Holographic Imaging      WaferGen Biosystems      BennuBio, Inc. Minos Biosciences     

Illumina Acquires Fluent BioSciences Inc. to Enhance Single-Cell Analysis! Illumina, a global leader in DNA sequencing, has acquired Fluent BioSciences, an innovator in single-cell technology, effective today. "This acquisition strengthens our multiomics growth strategy," said Steven Barnard, CTO of Illumina. "Fluent's accessible single-cell methods will accelerate our multiomics solutions." Fluent's technology simplifies single-cell analysis, removing the need for expensive instrumentation and microfluidic consumables. Their latest release, PIPseq™ V, excels in detecting diverse cell types and offers scalability from 100 to 1 million cells. By combining Fluent’s technology with Illumina’s sequencing and informatics solutions, including Partek Flow, customers will benefit from a comprehensive and economical solution for single-cell analysis. Fluent’s team will join Illumina, and PIPseq V will be integrated into Illumina’s product line. Illumina remains committed to its existing single-cell partnerships and an open NGS platform. The acquisition, closed on July 9, 2024, was funded with cash on hand. #illumina #biotech #dna #sequencing #singlecell #multiomics #genomics #research #innovation #biotechnology #science #cellanalysis #bioinformatics #techacquisition #pipseq #discovery #genomicresearch #fluentbiosciences #ngs #technology #healthcare

𝐍𝐞𝐱𝐭 𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐒𝐞𝐪𝐮𝐞𝐧𝐜𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞 𝐭𝐨 𝐇𝐢𝐭 $𝟐𝟕 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/dVYfZX-K The size of global next generation sequencing market in terms of revenue was estimated to be worth $13 billion in 2022 and is poised to reach $27 billion by 2027, growing at a CAGR of 15.7% from 2022 to 2027 Companies Operating in this Market Globally 10x Genomics BGI Genomics Agilent Technologies Bio-Rad Laboratories GenapSys Roche Illumina Oxford Nanopore Technologies NanoString Technologies, Inc.  PACIFIC BIOSCIENCES OF CALIFORNIA, INC. WHICH WILL DO BUSINESS IN CALIFORNIA AS PAC BIO, INC. QIAGEN PerkinElmer Thermo Fisher Scientific

In the fast-paced world of biopharma, quick actions and variability in early development are key to success. This demands high-throughput, automated techniques, and skilled professionals ready to take risks and adopt new methods. Watch on-demand 'Alone but Not Lonely: Designing an Outgrowth-Promoting Environment for Single Cell Cloning' to discover how the CellCelector platform is revolutionizing cell line development, host cell engineering, and cell adaptation. Learn how FyoniBio FyoniBio GmbH: Overview | LinkedIn has successfully integrated CellCelector to advance biopharmaceutics for both autologous and allogeneic cell therapies. More reasons to watch: ✅ How to identify key development and manufacturing challenges ✅ Commercial scalability strategies for late-stage cell therapies ✅ Ways to drive innovation to accelerate the delivery of cell therapies to patients faster How, when, and why to leverage state-of-the-art facilities ✅ The importance of end-to-end supply chain management Watch now: https://ow.ly/qWyr50SsBVH #Biopharma #Innovation #CellTherapy #CellCelector #FyoniBio